Attention Investors
Kindly note the Change in PAY IN for BSE A/C No. : 1201250000000691 (CDSL), if you have an NSDL A/C, kindly use INTER DEPOSITORY SLIP. For assistance, please call OR contact: Mr. Dadu, 98339 89807 / 022-6145 1000.    |   Exchanges / Depository: Prevent Unauthorized Transactions in your Trading / Demat account --> Update your Mobile Numbers / email IDs with your Stock Brokers / Depository Participant. Receive alerts on your Registered Mobile / email IDs for trading account transactions and all debit and other important transactions in your demat account directly from Exchange / Depository on the same day ......................Issued in the interest of Investors."     |    KYC : "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."     |    ASBA-IPO : "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
 ««+1  ««-1
 
 
ERIS Lifesciences LtdIndustry : Pharmaceuticals - Indian - Formulations
BSE Code:540596NSE Symbol: ERISP/E(TTM):152.08
ISIN Demat:INE406M01024Div & Yield %:0EPS(TTM):8.54
Book Value(Rs):189.2952734Market Cap ( Cr.):17679.79Face Value(Rs):1
    Change Company 
( In Cr)
 Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019
INCOME :      
Sales Turnover 1528.281340.371215.731108.831020.23896.54
Excise Duty0.000.000.000.000.000.00
Net Sales1528.281340.371215.731108.831020.23896.54
Other Income 34.8317.2628.9910.0014.7332.50
Stock Adjustments 13.15-8.50-2.4912.57-17.4713.40
Total Income1576.261349.131242.231131.401017.49942.44
EXPENDITURE :      
Raw Materials 293.31227.88197.16211.08146.88145.75
Power & Fuel Cost4.464.414.013.894.543.34
Employee Cost 331.67252.52220.11207.02191.73166.77
Other Manufacturing Expenses 16.8011.507.477.1610.624.85
Selling and Administration Expenses 319.25242.67215.51181.66219.34251.38
Miscellaneous Expenses 122.1387.7884.9393.1373.934.09
Less: Pre-operative Expenses Capitalised0.000.000.000.000.000.00
Total Expenditure1087.61826.75729.18703.93647.04576.17
Operating Profit488.64522.38513.04427.47370.44366.27
Interest 57.4220.813.050.941.9722.90
Gross Profit431.22501.57509.99426.53368.47343.37
Depreciation102.3964.6651.4637.6444.8831.59
Profit Before Tax328.83436.91458.53388.89323.59311.78
Tax57.6476.5080.1770.1857.4968.87
Fringe Benefit tax0.000.000.000.000.000.00
Deferred Tax-28.52-37.59-38.83-31.90-25.17-42.47
Reported Net Profit299.71398.01417.19350.61291.27285.38
Extraordinary Items 2.795.17-1.722.334.491.08
Adjusted Net Profit296.92392.84418.91348.28286.78284.30
Adjst. below Net Profit -2.76-0.15-1.01-1.28-100.21-0.10
P & L Balance brought forward2190.211892.281557.741283.091139.01853.73
Statutory Appropriations 0.000.000.000.000.000.00
Appropriations 0.0099.9381.6574.6846.980.00
P & L Balance carried down2487.162190.211892.281557.741283.091139.01
Dividend0.0099.9381.6574.6838.970.00
Preference Dividend0.000.000.000.000.000.00
Equity Dividend %0.00735.00601.00550.00287.000.00
Earnings Per Share-Unit Curr22.0329.2730.6925.8221.4520.75
Earnings Per Share(Adj)-Unit Curr22.0329.2730.6925.8221.4520.75
Book Value-Unit Curr185.55163.39141.11116.0395.7284.06